Cocaine N-acetylcysteine

ApprovedSmall molecule

Cocaine N-acetylcysteine is one of 24 small molecule programs targeting Cocaine Use Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cocaine Use DisorderActive, not recruiting

Cocaine Use DisorderApproved

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Cocaine Use Disorder

#DrugCompanyPhaseTrials

Rocaltrol

Alnylam Pharmaceuticals

Actos

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 4

Pitocin

Ozempic

2 6

Vraylar

AbbVie

Phase 2

1 7

Revia

Teva

Phase 2

1 8

Suboxone

IIndivior Inc.

Phase 2

1 9

Lorcaserin

Eisai

Phase 2

3 10

Cocaine N-acetylcysteine

HHospital de Clinicas de Porto Alegre

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cocaine Use Disorder1 trial

Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.

Unknown status·HHospital de Clinicas de Porto Alegre·Phase 4·NCT03018236·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cocaine N-acetylcysteine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cocaine N-acetylcysteine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cocaine N-acetylcysteine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital de Clinicas de Porto Alegre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHospital de Clinicas de Porto Alegre

Cocaine N-acetylcysteine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cocaine Use Disorder1 trial

References

Drug Info

Quick Facts

Related News